To PET or not to PET, that is the question

Lymphoma is one of the most chemosensitive tumors, but not all patients respond equally to the same chemotherapy. Therefore, individualized approaches are warranted,1 e.g. pre-treatment and post-treatment approaches. The former includes identification of prognostic factors2 and construction of prognostic indexes.1,3 The latter includes detection of measurable residual diseases and imaging response evaluation and further aims at treatment modification according to…